Melanotan I
An α-MSH analogue (afamelanotide) marketed in Europe for erythropoietic protoporphyria.
How it works
Selectively activates MC1-R on melanocytes to upregulate eumelanin synthesis, providing photoprotection.
Reported benefits
- Significantly reduces phototoxic reactions in EPP patients
- More selective MC1-R action than Melanotan II
- Provides UV-independent tanning
Dosage & administration
Approved EU implant delivers 16 mg subcutaneously every 2 months in EPP.
Dosing information is summarised from published clinical and pre-clinical literature for research purposes only and does not constitute medical advice.
Clinical & pre-clinical evidence
Afamelanotide for erythropoietic protoporphyria
New England Journal of Medicine · 2015
Significantly increased pain-free sun exposure vs placebo.
Safety & warnings
- Long-term skin-cancer surveillance required
- Generally well tolerated; pigment-change side effects expected
For research use. Consult a licensed clinician before any human application. Not for use in pregnancy, lactation, or active malignancy without specialist supervision.
Available presentations
10 mg
MT1
Box of 10 · $186
Single vial · $372
Related guides
Semax
A Russian heptapeptide derived from ACTH(4-10) with neuroprotective and pro-cognitive activity.
Selank
A synthetic tuftsin analogue with anxiolytic, nootropic, and immunomodulatory effects.
DSIP
Delta Sleep-Inducing Peptide, a nonapeptide identified in cerebral venous blood of rabbits during sleep.